SCHEMBL5366450

SCHEMBL5366450

O=C1Nc2ccc(CCCl)cc2C1=Cc1ccc(F)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MDM2 Q00987 4/20 0.48
RPS6KA3 P51812 1/20 0.48
KDR P35968 1/20 0.44
NTRK1 P04629 3/20 0.44
CCNE1 P24864 2/20 0.42
CDK2 P24941 2/20 0.42
CCNE2 O96020 1/20 0.42
LRRK2 Q5S007 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135626 0.88 MDM2 (0.50) MDM2RPS6KA3LRRK2PSEN1PSEN2
SCHEMBL7134255 0.87 FLT3 (0.54) FLT3MEN1KMT2AMDM2RPS6KA3
SCHEMBL7136372 0.86 LRRK2 (0.49) MDM2KDRNTRK1LRRK2PSEN1
SCHEMBL5377214 0.86 FLT3 (0.47) FLT3MEN1KMT2AMDM2RPS6KA3
SCHEMBL7139603 0.85 MEN1 (0.49) FLT3MEN1KMT2ARPS6KA3LRRK2
SCHEMBL7136594 0.81 NPC1 (0.62) FLT3MEN1KMT2ARPS6KA3KDR
SCHEMBL7133366 0.81 NTRK1 (0.53) KDRNTRK1LRRK2PSEN1PSEN2
SCHEMBL7139535 0.81 LRRK2 (0.49) FLT3MEN1KMT2ARPS6KA3KDR
SCHEMBL7137072 0.80 NPC1 (0.50) FLT3MEN1KMT2ARPS6KA3KDR
SCHEMBL5361064 0.79 RAF1 (0.46) MDM2RPS6KA3LRRK2PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK FLT3 395/4885MEN1 3855/4885KMT2A 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.